Quick Answer
Bionano Genomics, Inc. reported Cash and Equivalents of $2.99 million for fiscal year 2025.
Bionano Genomics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $2.99M | -67.4% |
| 2024 | $9.17M | -48.9% |
| 2023 | $17.95M | +252.5% |
| 2022 | $5.09M | -79.3% |
| 2021 | $24.57M | -36.1% |
| 2020 | $38.45M | +122.1% |
| 2019 | $17.31M | +4.8% |
| 2018 | $16.52M | +1516.9% |
| 2017 | $1.02M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.06M | -65.1% | -14.0% |
| June 30, 2025 | $3.56M | -65.8% | -1.7% |
| March 31, 2025 | $3.62M | -77.0% | -60.5% |
| December 31, 2024 | $9.17M | -48.9% | +4.3% |
| September 30, 2024 | $8.79M | -74.6% | -15.6% |
| June 30, 2024 | $10.43M | -29.8% | -33.8% |
| March 31, 2024 | $15.76M | +284.0% | -12.2% |
| December 31, 2023 | $17.95M | +252.5% | -48.1% |
- Bionano Genomics, Inc. showed a decrease of -67.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2025 period, Bionano Genomics, Inc.’s cash and equivalents has grown by 192.6% (from $1.02 million to $2.99 million).
- The most recent figure is from Bionano Genomics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: